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facilitates rehabilitation after surgery.[3,4] This drug 
is easy to administer and has the potential to be 
administered as a routine practice for diﬀ erent surgeries. 
Intravenous lidocaine has analgesic, antihyperalgesic, 
and anti-infl ammatory properties. It can reduce the 
postoperative infl ammatory response by blocking neural 
transmission at the site of tissue injury, thus aĴ enuating 
neurogenic infl ammation.[3-7] The objective of this study 
was to evaluate the analgesic eﬀ ects of adding lidocaine 
1% to 10 and 20 mg morphine (daily) in IV PCA aĞ er 
orthopedic surgeries. Due to the paucity of studies 
on the postoperative use of lidocaine in acute pain 
management, we tried to focus on its analgesic eﬀ ects 
in acute postoperative period in this study.
MATERIALS AND METHODS
Considering α = 0.05, β = 20%, and the calculation 
power as 80%, the study population consisted of 
50 patients. After obtaining approval from the 
institutional research commiĴ ee with code IUMS-931, 
INTRODUCTION
Patient-controlled analgesia (PCA) is one of the best 
postoperative analgesic methods.[1] Opioids are the most 
common drugs used in IV pumps for pain management, 
but they may cause nausea/vomiting and respiratory 
problems.[1,2] On the other hand, in some cases, it is 
diﬃ  cult to reduce opioid doses because of the severe 
pain caused during the first few days. Therefore, 
it has been observed that adding local anesthetics, 
ketamine, adrenergic alpha-2 agonists, antihistamines, 
and nonsteroidal anti-infl ammatory drugs to opioids 
in PCA to enhance the quality and length of analgesia 
and sedation reduces the opioid doses needed and its 
side eﬀ ects, including nausea/vomiting and itching.[2]
Lidocaine, a local anesthetic which inhibits sodium 
channels, has anesthetic and analgesic eﬀ ects when 
injected locally or intravenously. It has been shown 
that intravenous lidocaine injection can reduce 
postoperative pain and opiate consumption, and 
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60 patients with American Anesthesiology Score (ASA) 
I and II, candidates for orthopedic tibia open reduction 
internal fi xation (ORIF) surgery (between November 
2008 and August 2009), were enrolled in this double-
blinded clinical trial aĞ er they were informed of the study 
method and their wriĴ en consent was obtained. The 
patients were divided into three equal groups through 
simple random sampling. The exclusion criteria were: 
patients with a history of epilepsy, diabetes, kidney 
diseases, hypertension, heart block, or addiction to drugs, 
severely obese patients, and patients with a medical 
history showing allergy to lidocaine and opioids. General 
anesthesia method was the same in all patients. AĞ er 
performing complete monitoring (ECG, pulse oximetry, 
blood pressure, and ETCO2) and preoxygenation and 
premedication with midazolam and fentanyl, induction 
was made by injection of propofol plus cisatracurium. 
After intubation, anesthesia was maintained with 
propofol infusion. AĞ er undergoing surgery and gaining 
complete consciousness, the patients were transferred to 
a ward and were included in this study for a maximum of 
4 h aĞ er surgery. Postoperative analgesia was maintained 
with lidocaine (Lignodic 1%; Caspian, Rasht, Iran) using 
100 ml intravenous infusion pumps at a dosage of 0.8 mg/
kg/h with 4-6 ml/h fl ow rate [3-7] The pump solution in the 
fi rst group contained lidocaine 1% plus 20 mg morphine 
(Darupakhsh, Tehran, Iran) (LM20), in the second group 
contained lidocaine 1% plus 10 mg morphine (LM10), 
and in the third group (the control group) contained 
only 20 mg morphine (M20). The patients were randomly 
assigned to receive one of these pumps. The lockout 
interval was fi xed as 15 min. The researcher was not 
aware of the contents of the pumps, as another colleague 
prepared them. Patients were monitored every 12 h 
for 48 h to check for their Visual Analog Scale (VAS)/
Verbal Rating Scale (VRS), extra opioid doses, nausea/
vomiting, sedation score, satisfaction score (excellent, 
good, average, dissatisfied),[3,4,6,7] and demographic 
scores, which were recorded in their questionnaires by 
a colleague who was not aware of the study group. The 
defi nitions of the measured items are as follows:
Visual analog scale (VAS)
On a ruler scale from 0 to 10: 0 = no pain, 10 = most severe 
pain imaginable.
Verbal rating scale (VRS)
1 = No pain; 2 = mild pain; 3 = average pain; 4 = severe pain
Sedation score
0 = Restless; 1 = calm; 2 = sleepy; 3 = confused but responds 
to verbal instructions; 4 = no response to verbal instructions; 
5 = no response to painful stimulations.
Nausea/vomiting score
1 = No vomiting/nausea; 2 = mild nausea/vomiting with no 
need for medicine; 3 = nausea and need for medicine; 4 = no 
response to a dose of anti-nausea medicine.
Satisfaction score
1 = Excellent; 2 = good; 3 = average; 4 = dissatisfi ed.
In the event that patients experienced side eﬀ ects or did not 
achieve pain control (VAS ≥ 4 and average or high VRS), the 
content of the pump and dosage were changed as follows:
• VAS > 4: Increased lidocaine by 20% and administered 
2 mg morphine IV injection
• Only nausea: Administered metoclopramide 10 mg IV 
injection
• Any symptoms of lidocaine poisoning: Stopped the 
pump
In case VAS was <1 or there was mild VRS at 48 h aĞ er PCA, 
lidocaine dose was cut by 50% every 12 h and then stopped. 
Additionally, the patients were checked for probable side 
eﬀ ects like drowsiness, giddiness, and lip tingling.
In order to evaluate the gathered statistical data, SPSS 11.5 
soĞ ware was used. One-way analysis of variance (ANOVA) 
and Friedman and Duncan test were utilized to examine 
VAS/VRS, chi-square test was used for checking nausea/
vomiting, and Hawke post-test was used to evaluate how 
much extra opioid was needed and the total opioid used.
RESULTS
Sixty patients who were candidates for lower extremity 
orthopedic surgery entered this study. The fl ow diagram is 
given in Figure 1. The diﬀ erence among the three groups’ 
demographic data (age, sex, weight, height, operation 
duration, ASA) was not statistically signifi cant [Table 1].
Principal fi ndings of the study in both groups included 
the scores of pain, sedation, average morphine dose, and 
satisfaction [Table 2].
Mean VAS/VRS scores using one-way ANOVA and Duncan 
tests were signifi cantly lower in the fi rst group (LM20) 
compared to the other two groups on the fi rst day (P < 0.01 
and <0.05, respectively).
On the second day, these test results displayed lower mean 
VAS/VRS scores in the fi rst group (LM20) compared to 
the other two and the diﬀ erence was statistically signifi cant 
(P < 0.01 and <0.05, respectively). 
The fi gure for the number of patients in need of extra opioid 
was 10% in the fi rst group, 30% in the second group, and 
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25% in the third group. Chi-square test results displayed a 
statistically signifi cant diﬀ erence (P < 0.01). Hawke post-test 
showed a statistically signifi cant diﬀ erence between the fi rst 
group and the other two groups concerning the amount of 
morphine used (P < 0.01).
Although the extra morphine dose that was administered 
was larger in the second group (LM10) than in the other 
two groups, the total morphine dose used (average 
total morphine in the pump and extra morphine 
administered) was noticeably less in the second group 
than in the other two.
The side effects are listed in Table 3 and there was 
no statistically significant difference among the three 
groups (P > 0.1).
Sedation scores on 2 days were measured. On the fi rst day, 
the number of patients with sedation score ≥2 (≥median) 
was 3, 9, and 7 in the three groups, respectively, and on the 
second day, the number was 2, 8, and 6, respectively. There 
were no diﬀ erences in between the groups as measured by 
median test (P = 0.116, P = 0.092). 
Satisfaction score was measured by chi-square test and 
was signifi cantly beĴ er in the fi rst group on the second 
day (P = 0.004). 
Nausea/vomiting scores were measured and compared 
between groups by chi-square test, and no significant 
diﬀ erence was between them (P = 0.366, P = 0.402).
DISCUSSION
Studies show that lidocaine can be eﬀ ective in managing 
pain by blocking the sodium channels and possibly by 
having an inhibiting eﬀ ect on N-methyl-ё-aspartate (NMDA) 
receptors and protein G receptors because it can control the 
spontaneous impulses of pain in the posterior horn of the 
spinal cord and injured peripheral nerves. On the other hand, 















Number of patients 20 20 20
Sex (men/women)† 11/9 12/8 10/10 0.2
Age (years) 39.6±10.2 38.2±11.1 2.11±5.37 0.3
Height (cm) 167±9 170±10 172±6 0.15
Weight (kg) 72±12 68±11 71±10 0.23
ASA (I, II) 13/7 13/7 13/7 1.00
Operation duration (h) 3.8±0.5 3.5±0.6 3.4±0.9 0.12
Anesthesia duration (h) 4.2±0.45 4.1±0.5 3.9±0.7 0.20
†The difference among the three groups was not statistically signifi cant (P > 0.05)
Figure 1: Flowchart
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it controls aﬀ erent synapses in the transmission path, which 
also aﬀ ects the posterior horn of the spinal cord.[7-10]
Lidocaine causes the selective aĴ enuation of C fi bers in 
the posterior column of the spiral cord, and thus can be 
eﬀ ective in controlling the pain pathway.[10] The spura 
spinal analgesic mechanism of lidocaine is due to the 
changes brought about in the structure of the anterior brain, 
especially in cingulate cortex.[11-13]
In 1992, MarcheĴ ini et al. discussed the analgesic eﬀ ect of 
lidocaine infusion in controlling and relieving neuropathic 
pain, mechanical hyperalgesia, and postherpetic neuralgia 
aĞ er herpes.[14] In Rathmell and Ballantyne’s extensive meta-
analysis in 2005, the eﬀ ects of the systematic use of lidocaine 
in controlling neuropathic pain were examined and it was 
noted that lidocaine was more effective in controlling 
spontaneous responses than stimulated responses.[15]
Schwartzman et al. examined the effect of five daily 
infusions of lidocaine in patients suﬀ ering from severe 
complex regional pain syndrome and noted that the 
injection reduced mechanical and thermal sensitivity to 
pain in these patients.[16] Yardeni et al. studied the eﬀ ect of 
lidocaine infusion before the operation on controlling the 
production of infl ammatory mediators like interleukin-1 
and -6 and the surgery-induced immune alterations. 
They found that the lidocaine infusion controlled the 
infl ammatory responses considerably and reduced the 
postoperative infl ammation.[17,18] In the study conducted 
by Thomas et al., it was found that intravenous lidocaine 
can have a remarkable eﬀ ect on the phantom pain and 
opioid-resistant pain.[19]
Results from our study show that adding lidocaine 1% to 
20 mg morphine in the IV PCA aĞ er orthopedic surgery 
reduced the pain score without causing side eﬀ ects. This 
pain-reducing response to lidocaine in our study and other 
studies can be a guide for treatment with Oralsodium 
channel blocking agents, such as Mexiletine, Gabapentin, 
or Duloxetine (antidepressant).[7,13,15,20,21]
Opioids are the most common drugs used in patient-
controlled intravenous analgesia pumps (PCIA), but there 
has always been a concern about their overdose and side 
eﬀ ects. This is the reason why lidocaine was examined in 
this study as an auxiliary medicine to morphine in PCIA, 
and its probable capacity for decreasing the need for opioids 
was tested. According to the fi ndings of our current study, 
adding lidocaine 1% (50 mg/h) to morphine infusion of 
1 mg/h not only relieved pain and reduced the need for 
extra opioid doses, but also enhanced satisfaction without 
any side eﬀ ects. However, adding lidocaine to morphine 
infusion of 0.5 mg/h was not noticeably successful. Taking 
into account the lack of any side eﬀ ects resulting from 
lidocaine poisoning in these patients, it appears that 
lidocaine 1% at the mentioned infusion rate leads to no 
considerable side eﬀ ects.
In a study by Gagnon et al. on patients suﬀ ering from spinal 
chord injuries with severe neuropathic pain, it was noted 
that lidocaine infusion at less than 50 mg/h (similar to the 
concentration in our study) did not have any notable eﬀ ects 
on these patients’ pain control and hyperalgesia.[22] This does 
not agree with the fi ndings of our study. The discrepancy 
may originate from the fact that in our study, acute pain 
has been dealt with.
In another study on patients suffering from neuralgia 
aĞ er herpes, lidocaine infusion of 50 mg/h resulted in pain 
control and less sensitivity to mechanical stimulation. The 
eﬀ ects can even be compared to higher than 100 mg/h 
infusions of lidocaine.[23] These fi ndings agree with the 
results of the fi rst group (LM20) in our study.
Table 2: Findings of the study in the three groups (pain 














First day VAS 2.15±0.2 2.75±0.2 2±0.25 <0.01
Second day VAS 1.88±0.1 2.74±0.3 2.40±0.3 <0.01
Mean VAS 2.05±1.5 2.74±0.25 2.45±0.25 <0.05
Mean ﬁ rst day VRS 1.3±0.6 2.4±0.6 2.1±0.6 <0.05
Mean second day VRS 1.4±0.5 2.3±0.7 2.3±0.5 <0.05
Morphine dose used on 
the ﬁ rst day (mg)*
6±0.4 20±0.5 16±0.3 0.001
Morphine dose used on 
the second day (mg)*
5±0.8 16±0.7 14±0.5 0.001
Average total morphine 
used (mg)*
44±0.9 36±0.8 52±0.4 <0.01
Satisfaction* 70% 45% 55% <0.05
†No statistically significant difference among the three groups; *The difference is 
statistically signifi cant; VAS = Visual analog scale; VRS = Verbal rating scale
Table 3: Number of patients with the side effects noticed 
in the three groups














Nausea/vomiting† 2 2 3 0.1
Urinary retention† 1 1 1 0.12
Giddiness† — – 1 0.18
Hallucination† – – – –
Higher than 2 sedation 
score†
2 2 1 0.1
†No statistically signifi cant difference among the three groups
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In Clarke et al.’s study, more than 200 mg/h infusion of 
lidocaine was used to control postoperative pain. It was 
noticed that this quantity can eﬀ ectively control moderate 
and severe pain without causing side eﬀ ects. Additionally, 
shorter hospitalization time of the group under study 
compared to the control group was one of the advantages 
of this method, which was economically considerable.[24]
In a study by AĴ al et al., lidocaine at a dose of 5 mg/kg/h 
controlled mechanical allodynia aĞ er brain strokes in central 
pain syndrome.[25] 
In the patients suffering from neuropathic pain, 
lidocaine infusion at 1 mg/kg/h was used, while the 
serum lidocaine levels were checked every 8 h. Then 
lidocaine concentration was increased in a way that its 
plasma concentration was kept below 8 μg/ml.[26] The 
fi ndings of the mentioned study show that this quantity 
was eﬀ ective in controlling pain. Of course, it must be 
noted that lidocaine has an active metabolite named 
monoethylglycinexylidide, which plays a role in lidocaine 
poisoning and anesthesia, but cannot be measured 
when serum lidocaine levels are checked. This raises the 
question of using high quantities of lidocaine. 
The work of other researchers shows that lidocaine (with 
plasma concentrations of 5-15 μg/ml) is safe and eﬀ ective 
in controlling pain. Despite many meta-analyses carried 
out so far, there are many issues surrounding safe and 
eﬀ ective intravenous lidocaine doses, all of which need 
more investigation. On the other hand, there are opposing 
views on the maximum allowed time for lidocaine infusion 
and a fi nal agreement is still to be reached.[25,26] Recently, 
more investigations have been done on the perioperative use 
of lidocaine, which have shown positive eﬀ ects in terms of 
beĴ er pain control and functional recovery and less opioid 
consumption.[27-31] 
In Schwartzman et al.’s study, lidocaine at 5 μg/ml plasma 
concentration was examined for 5 days to control  Complex 
Regional Pain Syndromepain and no side eﬀ ects were 
observed.[16] 
In conclusion, it seems that adding lidocaine to morphine in 
PCIA (when proper morphine concentration is chosen) can 
be a safe method with fewer complications in controlling 
postoperative pain and it can reduce the need for extra 
opioid doses. 
Limitations of the study
Since there is no contentious agreement on the dose 
of lidocaine and its infusion standards, more research 
regarding higher concentrations and longer duration of 
lidocaine infusion should be carried out. Additionally, 
it is recommended that the anti-infl ammatory eﬀ ects of 
lidocaine be examined in future studies.
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